Battle of Honey Springs

Acetryptine (INN) (developmental code name W-2965-A), also known as 5-acetyltryptamine (5-AT),^[1] is a drug described as an antihypertensive agent which was never marketed.^[2] Structurally, acetryptine is a substituted tryptamine, and is closely related to other substituted tryptamines like serotonin (5-hydroxytryptamine).^[2] It was developed in the early 1960s.^[2]^[1] The binding of acetryptine to serotonin receptors does not seem to have been well-investigated, although it was assessed at the 5-HT_1A and 5-HT_1D receptors and found to bind to them with high affinity.^[3] The drug may also act as a monoamine oxidase inhibitor (MAOI); specifically, as an inhibitor of MAO-A.^[4]^[5]

References

^ ^a ^b HARTIGAN JM, PHILLIPS GE (1963). "Tissue distribution and metabolism of 5-acetyltryptamine in the mouse". Biochem. Pharmacol. 12 (6): 585–8. doi:10.1016/0006-2952(63)90136-9. PMID 13953098.
^ ^a ^b ^c J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 6–. ISBN 978-1-4757-2085-3.
^ Glennon RA, Hong SS, Bondarev M, Law H, Dukat M, Rakhi S, Power P, Fan E, Kinneau D, Kamboj R, Teitler M, Herrick-Davis K, Smith C (1996). "Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors". J. Med. Chem. 39 (1): 314–22. doi:10.1021/jm950498t. PMID 8568822.
^ Veselovsky AV, Medvedev AE, Tikhonova OV, Skvortsov VS, Ivanov AS (2000). "Modeling of substrate-binding region of the active site of monoamine oxidase A". Biochemistry Mosc. 65 (8): 910–6. PMID 11002183.
^ Ramsay RR, Gravestock MB (2003). "Monoamine oxidases: to inhibit or not to inhibit". Mini Rev Med Chem. 3 (2): 129–36. doi:10.2174/1389557033405287. PMID 12570845.